Fig. 2.

CMAI physical symptoms with clinically meaningful levels at baseline in patients with psychosis of AD: relationship between signal-to-noise ratio in the placebo group and the percentage slowing of decline with risperidone. *For each item, slowing of decline with risperidone was determined as percentage improvement versus placebo, calculated as follows: $\frac{CFB\left(R\right)-CFB\left(P\right)}{CFB\left(P\right)}\ast 100$ Color coding corresponds with factors into which each item loaded, as described in Fig. 1 (red, Aggression; green, Restlessness; blue, Negativity; pink, Combination). Boxes A, B, and C indicate items with greatest to lowest effect sizes, respectively, and also the highest to lowest variation between patients. The items of Hoarding and Hiding, which did not load into any factor, show the largest deviation from this linear relationship. CFB, change from baseline; CMAI, Cohen-Mansfield Agitation Inventory; MSDR, mean-to-standard-deviation ratio; P, placebo; R, risperidone.